164 related articles for article (PubMed ID: 28057155)
1. [Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications].
Zhang LQ; Chen Y; Pan X; Xing YF; Shi MH; Chen YJ
Zhonghua Yi Xue Za Zhi; 2016 Dec; 96(48):3870-3874. PubMed ID: 28057155
[No Abstract] [Full Text] [Related]
2. [The level of soluble programmed death-1 in peripheral blood of patients with lung cancer and its clinical implications].
Xing YF; Zhang ZL; Shi MH; Ma Y; Chen YJ
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):102-6. PubMed ID: 22455965
[TBL] [Abstract][Full Text] [Related]
3. [Effects of anti-PD-L1 monoclonal antibody and EGFR-TKI on the expression of PD-L1 and function of T lymphocytes in EGFR-mutated lung cancer cells].
She Y; Pan X; Xing YF; Zhou T; Zhang ZL; Shi MH; Chen YJ
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):886-892. PubMed ID: 27998463
[No Abstract] [Full Text] [Related]
4. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
5. [Expression of PD-1/PD-L1 in lung adenocarcinoma and correlation with epidermal growth factor receptor mutation status].
Wang Y; Da JP; Wang XH; Song AP; Chen H; Zhang HL; Chen S; Wang DW
Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):854-858. PubMed ID: 28056301
[No Abstract] [Full Text] [Related]
6. Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib.
Sorensen SF; Demuth C; Weber B; Sorensen BS; Meldgaard P
Lung Cancer; 2016 Oct; 100():77-84. PubMed ID: 27597284
[TBL] [Abstract][Full Text] [Related]
7. [Level of soluble programmed death ligand 1 in pleural effusion and peripheral blood of patients with tuberculous pleural effusion and its clinical implications].
Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1543-6. PubMed ID: 25146741
[TBL] [Abstract][Full Text] [Related]
8. [Thyroid transcription factor-1 level is associated with epidermal growth factor receptor mutation status in patients with advanced lung adenocarcinoma].
Niu Y; Wang H; Zhang G; Ma J; Wei B; Ma Z
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):919-23. PubMed ID: 25609130
[TBL] [Abstract][Full Text] [Related]
9. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
[TBL] [Abstract][Full Text] [Related]
10. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
Luo L; Shu M; Li S; Cai Y
Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
[TBL] [Abstract][Full Text] [Related]
11. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Li H; Wang Y; Su F; Li J; Gong P
Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
[TBL] [Abstract][Full Text] [Related]
13. High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases.
Mori S; Motoi N; Ninomiya H; Matsuura Y; Nakao M; Mun M; Okumura S; Nishio M; Morikawa T; Ishikawa Y
Pathol Int; 2017 Jan; 67(1):37-44. PubMed ID: 27976463
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
[TBL] [Abstract][Full Text] [Related]
15. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
[TBL] [Abstract][Full Text] [Related]
17. Associations between epidermal growth factor receptor gene mutation and serum tumor markers in advanced lung adenocarcinomas: a retrospective study.
Pan YQ; Shi WW; Xu DP; Xu HH; Zhou MY; Yan WH
Chin Med Sci J; 2014 Sep; 29(3):156-61. PubMed ID: 25264883
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
Hayashi H; Chiba Y; Sakai K; Fujita T; Yoshioka H; Sakai D; Kitagawa C; Naito T; Takeda K; Okamoto I; Mitsudomi T; Kawakami Y; Nishio K; Nakamura S; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2017 Nov; 18(6):719-723. PubMed ID: 28623122
[TBL] [Abstract][Full Text] [Related]
19. Significance of programmed death-ligand 1 expression in resected lung cancer and its relationship with EGFR mutation.
Osoegawa A; Abe M; Takumi Y; Hashimoto T; Karashima T; Miyawaki M; Sugio K
Thorac Cancer; 2023 Aug; 14(24):2467-2472. PubMed ID: 37455369
[TBL] [Abstract][Full Text] [Related]
20. [Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].
Chen H; Yang X; Liu H; Ma K; Zhong J; Dong Z; Zhuo M; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):589-597. PubMed ID: 28935011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
